Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation, jcm@btobioinnovation.com     Business   Sanofi Pasteur and MedImmune collaborate to develop and commercialize MEDI8897 for the prevention of Respiratory Syncytial Virus (RSV) associated illness in newborns and infants in a deal worth $645 million. MEDI889, a highly potent monoclonal antibody that neutralizes RSV by binding the […]

    Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation, jcm@btobioinnovation.com     Mergers, Acquisitions and Joint Ventures   Takeda Pharmaceutical and PRA Health Sciences (Raleigh, NC, USA), a clinical CRO, establish a joint venture in Japan aimed at improving operating efficiencies and accelerate the “transformation” of its R&D organization. The change is a global effort that is […]

      Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation, jcm@btobioinnovation.com     Mergers, Acquisitions and Joint Ventures   Allergan acquires Zeltiq Aesthetics for $2.475 billion and increases its aesthetics portfolio with the US FDA approved flagship CoolScuplting System, based on its proprietary-cooling technology platform. The system works by gently cooling targeted fat cells in the body […]

  Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation, jcm@btobioinnovation.com   Business   Seattle Genetics (Bothell, WA, USA) acquires rights of Immunomedic’s (Morris Plain, NJ, USA) IMMU-132, as atreatment of solid tumors, in a deal worth up to $1.7 billion. IMMU-132, or sacituzimab govitecan, is an antibody drug conjugate (ADC) that contains SN-338, the active metabolite of irinotecan […]